Aegis Capital Corp. acted as Lead Bookrunning Manager on a $25 Million Initial Public Offering of Common Stock for Cingulate Inc. (NASDAQ: CING)
Cingulate Inc. completed a $25 million Initial Public Offering (IPO) of Common Stock, facilitated by Aegis Capital Corp. as the Lead Bookrunning Manager. The company is focused on developing next-generation pharmaceutical products using its proprietary Precision Timed Release™ (PTR™) technology, particularly for treating Attention Deficit/Hyperactivity Disorder (ADHD). Their products aim to offer improved treatment outcomes and daily dosing regimens. Cingulate's pipeline includes innovative formulations like CTx-1301 and CTx-1302, designed for rapid onset and extended efficacy.
- Raised $25 million to support product development and clinical trials.
- Innovative Precision Timed Release™ technology may provide superior treatment options for ADHD.
- Focus on a large market with high demand for effective ADHD treatments.
- The IPO may lead to dilution of existing shares.
- As a clinical-stage company, Cingulate faces risks associated with drug development and regulatory approval.
NEW YORK, NY / ACCESSWIRE / December 10, 2021 / Aegis Capital Corp. acted as Lead Bookrunning Manager on a
Cingulate Inc.
Cingulate Inc. is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates. CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) are engineered using an innovative, versatile platform technology that will enable the formulation and manufacturing of single-dose, multi-release tablets designed to deliver a rapid onset and last the entire active-day, while providing a controlled descent of drug to optimize treatment. Cingulate's formulation will be designed as a once-daily, multi-release tablet with clear differentiation and compelling advantages over current treatment options.
For more information visit: www.cingulate.com
About Aegis Capital Corporation
Aegis Capital Corporation ("Aegis") has been in the wealth management and investment banking business since 1984. Aegis is dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Aegis also provides research and sales and trading services to institutional investors. Aegis offers its investment representatives a conflict free service platform and is able to provide a full-range of products and services including investment banking, wealth management, insurance, retirement planning, structured products, private equity, alternatives, equity research, fixed income and special purpose vehicles.
For more information about this offering or Investment Banking Services please email Banking@aegiscap.com or call (212) 813-1010.
Brokerage and investment advisory services are offered through Aegis Capital Corporation, a member of FINRA and SIPC. Investment and insurance products offered are not insured by the FDIC or any other federal government agency, are not deposits or other obligations of, or guaranteed by, a bank or any bank affiliate, and are subject to investment risks, including possible loss of the principal amount invested.
SOURCE: Aegis Capital Corp.
View source version on accesswire.com:
https://www.accesswire.com/677032/Aegis-Capital-Corp-acted-as-Lead-Bookrunning-Manager-on-a-25-Million-Initial-Public-Offering-of-Common-Stock-for-Cingulate-Inc-NASDAQ-CING
FAQ
What is the size of Cingulate Inc.'s IPO on NASDAQ (CING)?
What does Cingulate Inc. specialize in?
What technology does Cingulate Inc. use for its drug delivery?
What are the key products being developed by Cingulate Inc.?
How does the IPO impact shareholders of Cingulate Inc.?
